Circulation. Heart failure
-
Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking angiotensin II signaling, augment natriuretic peptides by inhibiting their breakdown by neprilysin. The myocardial effects of ARNi have been little studied until recently. We hypothesized that LCZ696 attenuates left ventricular (LV) remodeling after experimental myocardial infarction (MI), and that this may be contributed to by inhibition of hypertrophy and fibrosis in cardiac cells. ⋯ LCZ696 attenuated cardiac remodeling and dysfunction after MI. This may be contributed to by superior inhibition of LCZ696 on cardiac fibrosis and cardiac hypertrophy than either stand-alone neprilysin inhibitor or angiotensin receptor blocker.
-
Randomized Controlled Trial
Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.
Invasive hemodynamic exercise testing is commonly used in the evaluation of patients with suspected heart failure with preserved ejection fraction (HFpEF) or pulmonary hypertension. Saline loading has been suggested as an alternative provocative maneuver, but the hemodynamic changes induced by the 2 stresses have not been compared. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01418248.
-
Randomized Controlled Trial
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart failure with preserved ejection fraction. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00887588.
-
Randomized Controlled Trial Observational Study
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF.
Outcomes associated with episodes of hypotension while hospitalized with acute decompensated heart failure are not well understood. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00475852.
-
Little is known about associations of calcium channel blockers (CCBs) with outcomes in patients with heart failure and preserved ejection fraction (EF). ⋯ In hospitalized older patients with heart failure, new discharge prescriptions for CCBs had no associations with composite or individual end points of mortality or heart failure hospitalization, regardless of the class of CCBs.